ArticleClinical ophthalmology (Auckland, N.Z.)2009
Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease.
Article in Clinical ophthalmology (Auckland, N.Z.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Evaluation and comparison of microperimetry and optical coherence tomography findings in patients with Behçet uveitis.International ophthalmology · 2024Article
- Teaching NeuroImage: Mobile Hypopyon as a Clinical Clue for the Diagnosis of Behçet Disease.Neurology · 2023Article
- A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease.BioMed research international · 2015Review
- Biologic agents in experimental autoimmune uveitis.International ophthalmology · 2014Review
- Pediatric uveitis: An update.Oman journal of ophthalmology · 2013Review
- Use of biologic agents in ocular manifestations of rheumatic disease.International journal of rheumatology · 2012Article
- [Ocular involvement in spondyloarthropathies: HLA B27 associated uveitis].Zeitschrift fur Rheumatologie · 2010Review
- Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection.Journal of ophthalmic & vision researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adamantiades-Behçet's disease (ABD) is a multisystemic vasculitic disease. It is most prevalent in the Eastern Mediterranean countries and the Eastern region of Asia. Its effect on the eye can range from mild to debilitating, resulting in total blindness. A necrotizing and obliterative vasculitis affects both arteries and veins of organs. Recurrent attacks of uveitis, oral aphthous ulcers, skin lesions, and genital ulcers are common. Topical and systemic corticosteroids have been the mainstay in the treatment of ocular inflammation for many years; however, due to the several known side effects of corticosteroids and thanks to scientific advances, more novel approaches to ABD treatment have been emerging. Antimetabolites such as methotrexate and azathioprine have been utilized with the latter showing positive results. Chlorambucil has been utilized effectively for ocular manifestations of ABD. Interferon alpha has shown encouraging results in the management of refractory ocular inflammation associated with ABD, either alone or in combination with other immunosuppressive agents. Surgical interventions to deal with complications from ABD can be safely done if adequate control of inflammation is achieved peri-operatively. Early detection and aggressive treatment, when needed, have proven to be essential in the management of this relentlessly explosive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.